Current Rheumatology Reports

, Volume 3, Issue 1, pp 24–28 | Cite as

Phosphocitrate as a potential therapeutic strategy for crystal deposition disease

  • Herman S. Cheung


The deposition of basic calcium phosphate and calcium pyrophosphate dihydrate crystals in articular tissues is probably an underrecognized event. Clinical observations indicate that exaggerated and uniquely distributed cartilage degeneration is associated with these deposits. Measurements of putative markers of cartilage breakdown suggest that these crystals magnify the degenerative process. In vitro studies reveal two potential mechanisms by which crystals cause degeneration. These involve the stimulation of mitogenesis in synovial fibroblasts and the secretion of metalloproteinases by cells that phagocytose these crystals. Approaches that may ameliorate the degenerative process may ensue from new information about how crystals form and how they exert their biologic effects.


cAMP Response Element Binding CPPD Basic Calcium Phosphate CPPD Crystal Crystal Deposition Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Howard JE: Studies on urinary stone formation: a saga of clinical investigation. Johns Hopkins Med J 1976, 139:239–252.PubMedGoogle Scholar
  2. 2.
    Tew WP, Mahle CD, Benavides J, et al.: Synthesis and characterization of phosphocitric acid, a potent inhibitor of hydroxylapatite crystal growth. Biochemistry 1980, 19:1983–1988. A paper reporting the synthesis and characterization of phosphocitrate for the first time.PubMedCrossRefGoogle Scholar
  3. 3.
    Cheung HS, Sallis JD, Mitchell PG, Struve JA: Inhibition of basic calcium phosphate crystal-induced mitogenesis by phosphocitrate. Biochem Biophys Res Commun 1990, 171:20–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Cheung HS, Sallis JD, Struve JA: Specific inhibition of basic calcium phosphate and calcium pyrophosphate crystalinduction of metalloproteinase synthesis by phosphocitrate. Biochim Biophys Acta 1996, 1315:105–111.PubMedGoogle Scholar
  5. 5.
    Brogley M, Cruz M, Cheung HS: Basic calcium phosphate crystal induction of collagenase 1 and stromelysin expression is dependent on a p42/44 mitogen-activated protein kinase signal transduction pathway. J Cell Physiol 1999, 180:215–224. A study providing evidence that phosphocitrate blocks the crystalinduced metalloproteinase 1 and 3 synthesis via inhibition of p42/p44 MAPK pathway.PubMedCrossRefGoogle Scholar
  6. 6.
    Krug HE, Mahowald ML, Halverson PB, et al.: Phosphocitrate prevents disease progression in murine progressive ankylosis. Arthritis Rheum 1993, 36:1603–1611. A paper showing that phosphocitrate can prevent disease progression in a murine model of crystal deposition disease.PubMedCrossRefGoogle Scholar
  7. 7.
    Cheung HS, Kurup IV, Sallis JD, Ryan LM: Inhibition of calcium pyrophosphate dihydrate crystal formation in articular cartilage vesicles and cartilage by phosphocitrate. J Biol Chem 1996, 271:28082–28085. A study demonstrating for the first time that phosphocitrate can inhibit the formation of CPPD and HA crystals in articular cartilage vesicle and cartilage explants.PubMedCrossRefGoogle Scholar
  8. 8.
    Cheung HS, Ryan LM: Phosphocitrate blocks nitric oxideinduced calcification of cartilage and chondrocyte-derived apoptotic bodies. Osteoarthritis Cartilage 1999, 7:409–412.PubMedCrossRefGoogle Scholar
  9. 9.
    Ryan LM, Cheung HS: Role of crystals in osteoarthritis. In Rheumatic Disease of America. Edited by Brandt KD. Philadelphia: W.B. Saunders Co., 1999:257–267.Google Scholar
  10. 10.
    Cheung HS, Mitchell PG, Pledger WJ: Induction of expression of c-fos and c-myc protooncogenes by basic calcium phosphate crystal: effect of beta-interferon. Cancer Res 1989, 49:134–138.PubMedGoogle Scholar
  11. 11.
    McCarthy GM, Mitchell PG, Cheung HS: Misoprostol, a prostaglandin E1 analogue, inhibits basic calcium phosphate crystal-induced mitogenesis and collagenase accumulation in human fibroblasts. Calcif Tissue Int 1993, 52:434–437.PubMedCrossRefGoogle Scholar
  12. 12.
    McCarthy GM, Cheung HS: The role of cyclic-3′,′-adenosine monophosphate in prostaglandin-mediated inhibition of basic calcium phosphate crystal-induced mitogenesis and collagenase induction in cultured human fibroblasts. Biochim Biophys Acta 1994, 1226:97–104.PubMedGoogle Scholar
  13. 13.
    Tew WP, Malis CD, Howard JE, Lehninger AL: Phosphocitrate inhibits mitochondrial and cytosolic accumulation of calcium in kidney cells in vivo. Proc Natl Acad Sci U S A 1981, 78:5528–5532.PubMedCrossRefGoogle Scholar
  14. 14.
    Brown MR, Sallis JD: In Urolithiasis and Related Clinical Research. Edited by Schwille PO, Smith LH, Robertson WG, Vahlensieck W. New York: Plenum Press, 1985:891–894.Google Scholar
  15. 15.
    Shankar R, Crowden S, Sallis JD: Phosphocitrate and its analogueN-sulpho-2-aino tricarballylate inhibit aortic calcification. Atherosclerosis 1985, 50:191–198.Google Scholar
  16. 16.
    Nair D, Misra RP, Sallis JD, Cheung HS: Phosphocitrate inhibits a basic calcium phosphate and calcium pyrophosphate dihydrate crystal-induced mitogen-activated protein kinase cascade signal transduction pathway. J Biol Chem 1997, 272:18920–18925.PubMedCrossRefGoogle Scholar
  17. 17.
    Derfus BA, Rachow JW, Mandel NS, et al.: Articular cartilage vesicles generate calcium pyrophosphate dihydrate-like crystals in vitro. Arthritis Rheum 1992, 35:231–240.PubMedCrossRefGoogle Scholar
  18. 18.
    Ryan LM, Kurup IV, Derfus BA, Kushnaryov VM: ATP-induced chondrocalcinosis. Arthritis Rheum 1992, 35:1520–1525.PubMedCrossRefGoogle Scholar
  19. 19.
    Hashimoto S, Ochs RL, Rosen F, et al.: Chondrocyte-derived apoptotic bodies and calcification of articular cartilage. Proc Natl Acad Sci USA 1998, 95:3094–3099.PubMedCrossRefGoogle Scholar
  20. 20.
    Ryan LM, McCarty DJ: Calcim pyrophosphate dihydrate crystal deposition disease, pseudogout, and articular chonodrocalcinosis. In Arthritis and Allied Conditions edn 13. Edited by Koopman WJ. Baltimore: Williams and Wilkins; 1996:2103–2125.Google Scholar
  21. 21.
    Hakim FT, Cranley R, Brown KS, et al.: Hereditary joint disorder in progressive ankylosis (ank/ank) mice. I. Association of calcium hydroxyapatite deposition with inflammatory arthropathy. Arthritis Rheum 1984, 27:1411–1420.PubMedCrossRefGoogle Scholar
  22. 22.
    Sallis JD, Meehan JD, Kamperman H, Anderson ME: Chemically modified phosphocitrate and entrapment in microparticles for sustained inhibition of biomineralization. Phosphorous, Sulfur and Silicon 1993, 76:281–284.Google Scholar
  23. 23.
    Tomlinson E, Burger JJ: In Methods in Enzymology. Edited by Widder KJ, Tomlinson E. New York: Academic Press, 1985:27–43.Google Scholar
  24. 24.
    Doyle DV, Dunn CJ, Willoughby DA: Potassium permanganate induced calcergy: a model to study the effects of drugs on hydroxyapatite crystal deposition. J Pathol 1979, 128:63–69.PubMedCrossRefGoogle Scholar
  25. 25.
    Shinozaki T, Pritzker KPH: Polyamines enhance calcium pyrophosphate dihydrate crystal dissolution. J Rheumatol 1995, 22:1907–1912.PubMedGoogle Scholar
  26. 26.
    Sallis JD, Wierzbicki A, Cheung HS: Calcium pyrophosphate crystal forms and the influence of phosphocitrate. Advances in Crystal Growth Inhibitory Technologies. Edited by Amzad A. Philadelphia: Plenum Press, 2001.Google Scholar
  27. 27.
    WierzbickiA, Cheung HS: Molecular modeling of inhibition of crystals of CPPD by phosphocitrate. J Mol Struct Theochem 1998, 454:287–291. Using newly developed molecular model technology, this study provides evidence for the first time to show how PC inhibits the CPPD crystal formation.CrossRefGoogle Scholar
  28. 28.
    Wierzbicki|A, Cheung HS: Molecular modeling of inhibition of hydroxyapatite crystal by phosphocitrate. J Mol Struct Theochem. 2001. Using similar modeling technology, this paper demonstrates how phosphocitrate can inhibit hydroxyapatite formation.Google Scholar
  29. 29.
    Wierzbicki A, Sikes CS, Sallis JD, et al.: Scanning electron microscopy and molecular modeling of inhibition of calcium oxalate monohydrate crystal growth by citrate and phosphocitrate. Calcif Tissue Int 1995, 56:297–304.PubMedCrossRefGoogle Scholar
  30. 30.
    Wierzbicki A, Sallis JD, Stevens ED, et al.: Crystal growth and molecular modeling studies of inhibition of struvite by phosphocitrate. Calcif Tissue Int 1997, 61:216–222.PubMedCrossRefGoogle Scholar
  31. 31.
    Kaplan RS, Mayor JA, Gremse DA, Wood DO: High level expression and characterization of the mitochondrial citrate transport protein from the yeast Saccharmocyes cerevisiae. J Biol Chem 1995, 270:4108–4114.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Herman S. Cheung
    • 1
  1. 1.Research ServiceMiami VA Medical CenterMiamiUSA

Personalised recommendations